TCMD: Solid Devices, But Needs Profit Clarity

TL;DR

Avisol Capital Partners analyzes Tactile Systems Technology (TCMD) as a medical device maker for lymphedema and venous issues.
Flexitouch Plus drives most revenue, with coverage from Medicare and VA for over 275 million Americans.
Strong sales potential offset by falling EBITDA, competition, regulations, and lawsuits call for investment caution.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)

The story at a glance

Avisol Capital Partners reviews Tactile Systems Technology (NASDAQ: TCMD), a company with promising devices but unclear growth path. It focuses on products like Flexitouch Plus for lymphedema and chronic venous insufficiency, backed by major insurer coverage. The piece comes after recent financial reports showing revenue gains amid risks.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)

Key points

TCMD makes at-home medical devices treating lymphedema and chronic venous insufficiency via pneumatic compression.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)
Flexitouch Plus is the main product and top revenue source, with strong reimbursement from Medicare, VA, and private insurers.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)
Products reach over 275 million Americans through insurer networks; company uses direct sales in the US.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)
Market cap stands at $311 million; recent financials show solid revenue but declining EBITDA and some misses.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)
Faces rising competition, regulatory hurdles, and ongoing legal issues that add uncertainty.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)

Details and context

Tactile Systems targets unmet needs in lymphedema care, where patients need daily compression therapy. Flexitouch Plus offers a user-friendly alternative to manual methods, helping with insurance approvals and patient adherence. Coverage by big payers like Medicare lowers barriers for users.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)

Still, the author flags profitability pressures from falling EBITDA despite revenue. Competition from other device makers could erode market share, while regs and lawsuits—common in medtech—might hit operations. At $311 million cap, the stock trades low versus recent growth reports of 12% yearly revenue to $329.5 million.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)[[2]](https://finance.yahoo.com/quote/TCMD)

Why it matters

Medtech firms like TCMD shape chronic care access for millions with lymphedema, balancing innovation against payer and regulatory pressures. Investors see revenue promise from insurer ties, but risks like EBITDA drops and competition mean waiting for proof of sustained gains. Watch Q2 fiscal 2026 results and legal updates for signs of clarity on path forward.[[1]](https://seekingalpha.com/article/4773497-tactile-systems-technology-interesting-devices-company-need-more-clarity)